EDGAR·FLOW

Valion Bio, Inc. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 76/100
What the filing says
On November 6, 2026, Valion Bio closed a financing tranche with 3i, LP: 3i purchased 700 Series B Preferred Shares and warrants to buy 21,539 common shares at $0.5182/share for $700,000 aggregate. The Series B Preferred Purchase Agreement termination date was extended from December 9, 2026 to December 9, 2027. 3i also holds a $13.637M Series C position and a $16.25M convertible note.
Why this rating

At $4M market cap, $700K closing plus $23.86M Series C option represents meaningful capital runway. Extension signals investor confidence and sustained fundraising ability.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.54 ▲ 0.00%
at our read · unknown
$0.54
+10 min · unknown
$0.53 ▼ 1.85%
+30 min · unknown
$0.54 ▼ 0.76%
+1 hr · unknown
$0.54 ▼ 0.72%
+4 hrs · unknown
$0.53 ▼ 1.30%

The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ VBIO · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.